∫—π∑÷°°“√ª√–™ÿ¡«‘∑¬“°“√«—§´’π §√—Èß∑’Ë 2 «—π∑’Ë 15-17 ¡‘∂ÿπ“¬π 2553 179
- PHAMBILI study (HVTN 503) °“√∑¥ Õ∫∑—Èß STEP ·≈– PHAMBILI »÷°…“‚¥¬„™â recombinant Adeno 5 (Ad 5) Vector „π°“√· ¥ßÕÕ°¢Õ߬’π gag, col ·≈– naf „π clade B º≈°“√∑¥ Õ∫æ∫«à“ «—§´’π‰¡à “¡“√∂ªÑÕß°—π°“√μ‘¥‡™◊ÈÕ‰¥â ·≈– Õ“ “ ¡—§√∑’Ë¡’·Õπμ‘∫Õ¥’μàÕ Ad 5 π—Èπ¬—ß¡’ ‚Õ°“ μ‘¥‡™◊ÕÈ ‰¥âß“à ¬¢÷πÈ ¥â«¬ ·μà∑ß—È π’ºÈ ≈¢Õß immunogenicity °≈—∫‰¥âº≈¥’ ‚¥¬ “¡“√∂°√–μÿπâ T cell ‰¥â„πÕ“ “ ¡—§√ à«π„À≠à À“°°≈à“« ‚¥¬ √ÿª·≈â«®–‡ÀÁπ«à“ T cell-based vaccine ‡æ’¬ßÕ¬à“߇¥’¬«‰¡à “¡“√∂ªÑÕß°—π°“√μ‘¥‡™◊ÕÈ ‰¥â «—§ ´’π‡Õ¥ å∑ ¥≈Õß√–¬–∑’Ë 3 „π ª√–‡∑»‰∑¬ „π°“√∑¥≈Õß Thai trial ¢Õß«—§´’π ‡Õ¥ å ∑’Ë∑¥ Õ∫„πÕ“ “ ¡—§√®”π«π°«à“À¡◊Ëπ §π ‰¥â„™â°√Õ∫·π«§‘¥·∫∫ prime-boost vaccine ‚¥¬ªŸæπ◊È (Prime) ¥â«¬ ALVAC ·≈â« °√–μÿâπ (Boost) ¥â«¬ AIDSVAX ´÷Ë߇ªìπ recombinant protein æ∫«à“ “¡“√∂ªÑÕß°—π °“√μ‘¥‡™◊ÈÕ‰¥âª√–¡“≥ 1 „π 3 ¢ÕßÕ“ “ ¡—§√∑—ÈßÀ¡¥ º≈®“°°“√∑¥ Õ∫¥—ß°≈à“«‰¥â 𔉪 Ÿà°“√√–¥¡π—°«‘∑¬“»“ μ√å∑—Ë«‚≈°Õ’°§√—Èß Àπ÷Ëß ‡æ◊ËÕ»÷°…“ protective immunity „π cohort π’È ë Õߧ姫“¡√Ÿâ„À¡à‡°’ˬ«°—∫°“√æ—≤π“ «—§´’π‡Õ¥ å ®“°°“√∑¥ Õ∫∑“ߧ≈‘π‘°√–¬–∑’Ë 3 ¢Õß«— § ´’ π ‡Õ¥ å „ πª√–‡∑»‰∑¬ ∑”„Àâ ° “√
æ—≤π“«—§´’π‡Õ¥ 嬗ߧߡ’§«“¡À«—ß ‡æ’¬ß·μà μâÕß„™â‡«≈“·≈–Õߧ姫“¡√Ÿâ ´÷ËßÕߧ姫“¡√Ÿâ„À¡à ∑’Ëπà“ π„® ‰¥â·°à 1. Critical Timing: Early Transmission and Infection Events (window of opportunity to prevent HIV infection) 1.1 ‡¡◊ËÕ¡’°“√ —¡º— ‡™◊ÈÕ∑“߇¬◊ËÕ ‡¡◊Õ° ‡™◊ÈÕ‰«√— ®–„™â‡«≈“‡æ’¬ß·§àÀ≈—°™—Ë«‚¡ß „π°“√‡¢â“ Ÿà target cell ‡™àπ dendritic cell ·≈– T cell ‡ªìπμâπ ®÷߇ªìπ ‘Ëß∑â“∑“¬«à“ À“° ‰¥â√—∫°“√ immunize ‚¥¬ prime ·≈– boost ·≈â«®–¡—πË „®‰¥âÕ¬à“߉√«à“ protective level À√◊Õ protective immunity π—Èπ¡’√–¥—∫∑’Ë ŸßæÕ„π ‡«≈“∑’Ë —¡º— ‡™◊ÈÕ 1.2 ° “ √ ∑ ¥ Õ ∫ «— § ´’ π „ π ª√–™“°√°≈ÿ¡à √—°√à«¡‡æ»°—∫ª√–™“°√°≈ÿ¡à heterosexual Õ“®¡’§«“¡·μ°μà“ß°—π„π‡√◊ËÕߢÕß vaccine design ‡æ√“–∂â“¡’‡æ» —¡æ—π∏å∑“ß ∑«“√Àπ—°·≈â«¡’‡™◊ÕÈ ‡¢â“‰ª ª√“°Ø«à“„π submucosal ¢Õß gut mucosa ´÷Ëß¡’ CD4 Õ¬Ÿà‡ªìπ ®”π«π¡“° ®÷ß∑”„À⇰‘¥°“√μ‘¥‡™◊ÈÕ‰¥âßà“¬ „π Õ¥’μ°“√∑¥≈Õß„π≈‘ß à«π„À≠à‡ªìπ ractal challenge ´÷Ë߉¥âº≈‡ªìπ false protection ∂÷ß ·¡â«“à ®–‡°‘¥ false protection „π ractal challenge ·μàÕ“®®–ªÑÕß°—π∑“ß vagina ‰¥â ‡π◊ËÕß®“°„π vaginal mucosa „π à«π submucosa π—Èπ¡’ CD4 ®”π«ππâÕ¬ ∑”„Àâ¡’ ‚Õ°“ μ‘¥‡™◊ÈÕ‰¥âπâÕ¬°«à“ ‡æ√“–°“√®–μ‘¥‡™◊ÈÕ ‰¥âπ—ÈπμâÕß recruit CD4 ¡“æÕ ¡§«√ ·μà